Powered by
ProtoKinetix Announces Start of Phase 1 & Phase 2 Clinical Trials for the use of AAGP(TM) PKX-001 Treated Islet Cells in the Treatment of Type 1 Diabetes

ProtoKinetix, Incorporated (OTC: PKTX) (the "Company" or "ProtoKinetix") ( www.protokinetix.com ) today announced the start of a Phase 1 first-in-human clinical trial of AAGP(TM) PKX-001 treated islet cells used in conjunction with the Edmonton Protocol for the treatment of Type 1 diabetes. The first patient has been treated under this protocol. The trial is being led by Dr. James Shapiro, MD, PhD, FRCSC, MSM FCAHS, AHS Director of Clinical Islet and Living Donor Liver Transplant Programs, Canad

Sign up for unrestricted access to 200+ subscription services.
Already have an account? Click here to login.

RelSci News & Alerts gets you:

  • 5 free articles a month from top subscription outlets like the Financial Times, New York Times, and Washington Post
  • Competitive business intelligence through daily data updates
  • Custom feeds on target high-value individuals, companies, industries, and topics delivered straight to your inbox